Drug: F 18 T807

PreclinicalSmall molecule

Drug: F 18 T807 is one of 4 small molecule programs targeting Familial Amyotrophic Lateral Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Amyotrophic Lateral SclerosisActive, not recruiting

Familial Amyotrophic Lateral SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Familial Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Miplyffa

ZZevraDenmark

Phase 3

1 2

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 1

1 3

ISIS 14803

Ionis Pharmaceuticals

Phase 1

1 4

Drug: F 18 T807

TTammie L. S. Benzinger, MD, PhD

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial Amyotrophic Lateral Sclerosis1 trial

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

Completed·TTammie L. S. Benzinger, MD, PhD··NCT02414230·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: F 18 T807. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: F 18 T807 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: F 18 T807. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tammie L. S. Benzinger, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTammie L. S. Benzinger, MD, PhD

Drug: F 18 T807

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News